Table 2 Detailed outcome data

Hu et al. (2021) [15]

mFOLFOXIRI + cetuximab

95.5%

15.5

Not reached

mFOLFOXIRI

76.5%

14.2

33.2

Modest et al. (2019) [16]

mFOLFOXIRI + panitumumab

87.3%

9.7

35.7

m FOLFOXIRI

60.6%

4

29.8

Assenat et al. (2011) [11]

FOLFIRINOX + cetuximab

80.9%

9.5

24.7

Fornaro et al. (2013) [14]

A slightly modified GONO-FOLFOXIRI + panitumumab

89%

11.3

Not reached

Garufi et al. (2010) [12]

Chronomodulated FOLFOXIRI + cetuximab

79.1%

14

37

Saridaki et al. (2012) [13]

FOLFOXIRI + cetuximab

70%

10.2

30.3